Wellington Partners is a leading European venture capital firm supporting outstanding entrepreneurs and their products on their way to market leadership. We have already invested in more than 50 early- and growth-stage life science companies, active in the fields of biotechnology, therapeutics, medical devices, diagnostics and digital health. We do not only provide financial resources, but also contribute our expertise, hard work and passion to help world class teams in building successful businesses of exceptional growth. Working hand in hand with our portfolio companies, we turn big ideas into big successes.
We provide world class entrepreneurs with the capital for the financing of breakthrough products with the potential to decisively improve current standard of care and, most importantly, the lives of patients. We proactively source deals and lead or co-lead financing rounds, from early stage to expansion stage and selected PIPE investments (Private Investment in Public Equity). Our ticket sizes typically range from EUR 2 million to EUR 20 million.
All-round support for all stages of growth
Providing funding is only one part of our business, with long-term commitment and active collaboration being the other. Our team consists of both MDs and PhDs and brings together a unique combination of passionate and committed people, extensive investment experience and company-building skills. Our role is to offer board level strategic support to entrepreneurs while they exercise operational control. Together with our global scientific and commercial network, we are in a position to organize financing rounds, accelerate preclinical and clinical development, regulatory approval processes, and drive successful market entry into the most important healthcare markets in Europe, the U.S. and Asia.
Successful exits
We know that success does not happen overnight and we are prepared to accompany entrepreneurs for as long as it might take to transform great ideas into great successes and ultimately deliver outstanding results for those we serve – patients, entrepreneurs, and the people and organizations that entrust us with their capital.
More than 20 of our portfolio companies have already achieved a successful exit or IPO.
Here are a few examples:
- Definiens
- Rigontec
- Themis Bioscience
- Invendo medical
- Sapiens
- Atopix Therapeutics
- Oxford Immunotec
- MTM Laboratories